[{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Insmed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Amikacin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liposome Inhalation Suspension","sponsorNew":"Taiba Healthcare \/ taiba Middle East FZ","highestDevelopmentStatusID":"12","companyTruncated":"Taiba Healthcare \/ taiba Middle East FZ"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Aspargo Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Taiba Healthcare \/ Taiba Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Taiba Healthcare \/ Taiba Healthcare"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"X4 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Mavorixafor","moa":"CXCR4","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Taiba Healthcare \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Taiba Healthcare"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiba Healthcare \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Taiba Healthcare"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"OMAN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiba Healthcare \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Elevar Therapeutics"}]